On Sunday, Duke announced that the Duke Human Vaccine Institute (DHVI) has received approval for a clinical trial that, if successful, could advance COVID care until a vaccine can be developed.
Approval means DHVI may launch Phase 1 clinical trial for one of the most promising antibody treatments against COVID-19.
“It would be a temporary treatment until a vaccine is developed,” Duke Today said in a statement.
DHVI is also developing a pan-coronavirus vaccine to combat future iterations of COVID-19 or similar viruses, as well as whether saliva could be used as an accurate indicator of COVID-19, according to Duke Today.
This video posted by Duke Health Development provides a more in-depth look at the trials and the potential of antibody therapy.